WASHINGTON, Aug. 19, 2026: President Donald Trump has selected Heidi Overton, a senior White House health policy aide and physician, as his choice to lead the U.S. Food and Drug Administration, putting a closely aligned administration official at the helm of one of the country's most powerful public-health agencies.
Overton, who serves as deputy director of the White House Domestic Policy Council, is expected to succeed Marty Makary, who resigned as FDA commissioner in May after roughly 13 months in the position. The nomination still requires confirmation by the U.S. Senate.
The choice places an experienced White House policy adviser, rather than a traditional FDA career official, in line to oversee an agency responsible for regulating medicines, vaccines, medical devices, food, tobacco products and other products used by millions of Americans.
Who is Heidi Overton?
Overton is a medical doctor with advanced training in clinical investigation. She earned her medical degree from the University of New Mexico and a Ph.D. in clinical investigation from the Johns Hopkins Bloomberg School of Public Health. She has also been board-certified in public health and general preventive medicine.
Her relationship with the Trump administration predates his second term. Overton previously served as a White House fellow during Trump's first administration and later worked at the conservative America First Policy Institute, where she became chief policy officer and held a leadership position at its Center for a Healthy America.
After Trump returned to the White House, Overton joined the administration's Domestic Policy Council and became an important participant in shaping its health agenda.
A key figure in Trump's health agenda
Overton has worked closely on several of the administration's major health initiatives.
Among the policies she has helped advance are changes to the childhood vaccination schedule, efforts to redesign federal nutrition guidance and negotiations involving pharmaceutical drug prices. She was also present at the White House when Trump signed an executive order concerning childhood vaccines on Aug. 10.
Her involvement has made her a prominent figure within the administration's “Make America Healthy Again,” or MAHA, agenda, associated with Health and Human Services Secretary Robert F. Kennedy Jr.
That background could make Overton particularly attractive to Trump as he seeks an FDA commissioner who is closely aligned with his administration's health-policy priorities.
At the same time, it is likely to make her Senate confirmation hearing closely watched.
FDA faces major challenges
Overton would inherit an agency experiencing significant disruption.
The FDA has gone through substantial leadership and staffing changes during the past year. Reuters reported that more than 3,000 employees, including senior officials, have left the agency, creating concerns about institutional stability and morale.
The next commissioner will therefore face the immediate challenge of restoring confidence inside the agency while ensuring that the FDA continues carrying out its regulatory responsibilities.
The agency's decisions affect a vast portion of the U.S. health-care system, from approving new drugs and medical devices to monitoring food safety and regulating tobacco and vaping products.
Vaccine policy likely to dominate scrutiny
One of the most politically sensitive issues surrounding Overton is vaccination policy.
She has been involved in the administration's efforts to alter childhood vaccine recommendations, including Trump's recent push to separate the combined measles, mumps and rubella vaccine into individual doses.
The issue is likely to receive significant attention during Senate confirmation proceedings because vaccination policy sits at the intersection of scientific evidence, federal regulation and political debate.
Senators are expected to question Overton about how she would balance the administration's policy objectives with the FDA's responsibility to base regulatory decisions on scientific evidence.
Senate confirmation could be difficult
Although Republicans control the Senate, Overton's confirmation is not guaranteed to be effortless.
Her supporters are likely to emphasize her medical background, public-health training and extensive experience working on federal health policy.
Critics, meanwhile, are expected to focus on her close alignment with Trump's health agenda and her involvement in controversial vaccine policies.
The Senate's health committee will likely examine her qualifications, views on drug regulation, vaccine policy, pharmaceutical pricing and the FDA's independence before the full Senate considers her nomination.
What happened to Marty Makary?
Overton's nomination follows a turbulent period under former FDA Commissioner Marty Makary.
Makary left the agency after about 13 months in the job. His tenure included disputes involving pharmaceutical companies, vaping regulation and vaccine policy.
His departure left the FDA without a permanent commissioner and intensified questions about the agency's direction under the Trump administration.
Acting Commissioner Kyle Diamantas has since overseen the agency, including efforts to accelerate drug-development initiatives and make regulatory changes.
Overton's selection would give the FDA a permanent nominee with a strong connection to the White House.
A different kind of FDA leadership
Traditionally, the FDA commissioner has been expected to combine scientific expertise with substantial experience navigating the agency's complicated regulatory structure.
Overton brings scientific and medical training, but much of her recent experience has been in policymaking rather than running a large regulatory organization.
That distinction could become an important part of the confirmation debate.
The FDA is a huge bureaucracy with responsibility for thousands of products and complex relationships with pharmaceutical companies, biotechnology firms, hospitals, researchers and consumers. Managing the agency requires not only policy knowledge but also the ability to oversee a large workforce and maintain regulatory consistency.
Pharmaceutical industry watching closely
The pharmaceutical and biotechnology industries will also be paying close attention to Overton's approach.
Drugmakers depend on the FDA for approval of new medicines, clinical-trial oversight, manufacturing standards and post-market safety monitoring.
Changes in FDA leadership can therefore affect investment decisions, drug-development timelines and expectations about future regulation.
Overton's involvement in the administration's pharmaceutical-pricing negotiations suggests that drug costs could be another important area during her tenure.
Rebuilding trust will be a central challenge
Perhaps Overton's biggest challenge will be rebuilding confidence in the FDA.
The agency is expected to make decisions that affect public health while operating under intense political scrutiny. Its commissioner must simultaneously respond to the president, Congress, scientists, industry and the public.
For Overton, the task will be particularly demanding because she enters the nomination process as someone already closely associated with the White House's health agenda.
Supporters are likely to view that connection as an advantage, arguing that she understands Trump's priorities and can implement them effectively.
Critics may see the same connection as a potential threat to the FDA's regulatory independence.
What comes next
Trump's selection now moves the focus to the Senate.
If confirmed, Overton would become responsible for stabilizing the FDA after months of leadership turnover while implementing the administration's broader health agenda.
She would also have to address major questions involving vaccine regulation, food safety, drug approvals, pharmaceutical prices, tobacco products and emerging medical technologies.
The appointment is therefore about more than replacing an FDA commissioner. It represents a significant test of how Trump's second-term health philosophy will shape the agency responsible for protecting Americans from unsafe food, medicines and medical products.
For Overton, the Senate confirmation process will provide the first major test of whether her close alignment with Trump's health priorities is viewed as a strength—or a liability—for leading the FDA.
Also Read: D.C. Welds 220 Manholes Shut for High-Speed Grand Prix